The Journal of Herbal Medicine, published by Elsevier GmbH in Germany, stands at the forefront of research in the dynamic and evolving field of complementary and alternative medicine. With an ISSN of 2210-8033 and an E-ISSN of 2210-8041, this journal has been contributing significant insights since its inception in 2011 and continues to be a vital resource through 2024. Recognized for its scholarly rigor, it holds a commendable Q2 ranking in the 2023 Scopus category for Complementary and Alternative Medicine, placing it in the upper echelons of its field with a rank of 32 out of 105 journals, marking it in the 70th percentile. The Journal of Herbal Medicine emphasizes the integration of traditional herbal therapies and modern scientific approaches, offering researchers, professionals, and students a platform for disseminating their findings and fostering an inclusive dialogue on natural medicine's role in healthcare. Although it is not an open-access publication, its commitment to high-quality research makes it an essential read for those wanting to explore the efficacy and application of herbal medicine in contemporary practice.

Fitoterapia is a prestigious journal published by Elsevier that specializes in the fields of drug discovery and pharmacology. Established in 1948 and featuring a comprehensive scope that encompasses all aspects of medicinal plants and their derivatives, this journal is a critical resource for researchers, professionals, and students interested in the pharmacological effects of natural products. With an impressive impact factor reflected in its Q2 ranking in both Drug Discovery and Medicine as well as a Q3 ranking in Pharmacology, Fitoterapia plays a vital role in promoting innovative research in the intersection of traditional medicine and modern pharmacological science. The journal’s commitment to quality is further highlighted by its rankings in Scopus, where it holds a notable position among peers in its field. Although Fitoterapia does not currently offer Open Access, its reputation for rigor and relevance makes it an indispensable asset for anyone engaged in herbal medicine research and development. Authors and researchers seeking to publish groundbreaking findings will find a welcoming platform to disseminate their work in this influential journal.

The Chinese Journal of Natural Medicines, published by the esteemed CHINESE JOURNAL NATURAL MEDICINES, plays a pivotal role in the exploration and advancement of complementary and alternative medicine. With an ISSN of 2095-6975 and an E-ISSN of 1875-5364, this journal is recognized for its commitment to high-quality research and innovative findings in the realms of drug discovery and miscellaneous medical fields. Operating from China, it has earned a prestigious reputation in the academic community, achieving Q1 status in Complementary and Alternative Medicine and Q2 rankings in both Drug Discovery and Miscellaneous Medicine as of 2023, solidifying its influence within the scientific discourse. Researchers and professionals will find valuable insights here as the journal explores the intersection of traditional natural medicines with modern pharmacological science, making it an essential resource for anyone dedicated to the field. With a convergence period from 2004 to 2024, the journal continues to champion open dialogue and disseminate significant findings critical for the development of effective natural therapies.

Annals of Phytomedicine - An International Journal is a leading publication dedicated to the exploration and advancement of phytomedicine, broadly encompassing research on medicinal plants, their bioactive compounds, and therapeutic applications. Published by UKAAZ Publications, this journal seeks to bridge the gap between traditional and modern medicinal practices, offering a platform for researchers, professionals, and students passionate about herbal therapies and their efficacy. With an ISSN 2393-9885 and E-ISSN 2278-9839, the journal adheres to stringent peer-review protocols to ensure the publication of high-quality research. Fostering open access to knowledge in a rapidly evolving field, Annals of Phytomedicine serves as an essential resource, promoting innovative findings and comprehensive reviews that drive the global discourse on phytotherapy. By engaging with this journal, readers can stay informed about the latest advancements, contributing significantly to the scholarly community and beyond.

The Journal of Ethnopharmacology, published by Elsevier Ireland Ltd, is a pivotal resource in the fields of Drug Discovery and Pharmacology, recognized as a Q1 journal in both categories as of 2023. With a rich history since its inception in 1979, this peer-reviewed journal provides a platform for rigorous research and innovative findings related to traditional medicinal practices and the therapeutic potential of natural products. The journal is ISSN 0378-8741 and E-ISSN 1872-7573, and it plays a vital role in advancing knowledge through its high-quality publications, which rank impressively at #35 out of 313 in Pharmacology and #19 out of 157 in Drug Discovery according to Scopus metrics. Although not open access, the journal aims to cater to a diverse audience of researchers, professionals, and students dedicated to exploring the intersection of ethnopharmacology and modern scientific inquiry. Its comprehensive scope encapsulates a multitude of studies spanning the globe, fostering a deeper understanding of how traditional practices can inform contemporary health solutions.

Advances in Traditional Medicine, published by SPRINGER, stands at the forefront of the Complementary and Alternative Medicine field, dedicated to exploring the intricate landscapes of traditional medical practices worldwide. With an impressive 2023 Q2 ranking and a Scopus rank of #30/105, this journal is committed to advancing scholarly discourse and innovation in the study and practice of traditional medicine, making it an essential resource for researchers, practitioners, and students alike. As an Open Access journal, it ensures wide accessibility to cutting-edge research and developments from 2020 to 2024, fostering collaboration and knowledge exchange in the global medical community. Based in Singapore, with operations linked to VAN GODEWIJCKSTRAAT 30, 3311 GZ Dordrecht, Netherlands, this journal not only enhances its reach but also enriches the academic landscape with its significant contributions to understanding the role of traditional medicine in contemporary healthcare.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Jundishapur Journal of Natural Pharmaceutical Products, published by BRIEFLAND in the Netherlands, serves as a pivotal platform for researchers and professionals in the realm of pharmacology and toxicology. With its ISSN 1735-7780 and E-ISSN 2228-7876, the journal has established itself since its inception in 2011, showcasing a commitment to advancing knowledge in natural pharmaceutical products through innovative research. In 2023, it earned a commendable ranking in the Q3 category for Pharmacology, Toxicology, and Pharmaceutics, reflecting its contribution to the field as evidenced by its position in the Scopus rankings. The journal aims to publish high-quality research articles, reviews, and case studies that explore the potential benefits and toxicological aspects of natural products. Although it currently does not offer open access, its rigorous peer-review process ensures that only impactful studies are disseminated, ultimately facilitating a deeper understanding of natural pharmaceutical innovations. For those engaged in this exciting and evolving field, Jundishapur Journal of Natural Pharmaceutical Products is an essential resource that not only expands scholarly discourse but also promotes safe practices in natural product utilization.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.